Medicenna Therapeutics Corp (MDNA.TO) has seen a noticeable increase in its stock price, reflecting positive investor sentiment.
In the latest trading session, Medicenna's stock rose by 2.44%, closing at CA$0.42. This uptick suggests a shift in how the market views the biopharmaceutical company, which focuses on developing innovative therapies for cancer treatment.
Investor takeaway: The rise in Medicenna's stock price may indicate growing confidence among investors, likely driven by recent advancements in its clinical studies and strategic decisions.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Medicenna Therapeutics Corp
MDNA.TO
MDNA.TO
Medicenna Therapeutics Corp
WealthAwesomeMarket cap
$33.69M
52W high
$1.97
52W low
$0.36
1W change
-6.41%
Beta
1.89
Analyst Price Targets
Based on analyst covering MDNA
Wall Street analysts forecast MDNA stock price to rise 776.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.20
+776.7% Upside
Current Price
C$0.36
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDNA's historical volatility
30-Day Vol
44.4%
Annualized
90-Day Vol
70.3%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.31
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.34 | C$0.30 – C$0.40 |
| 60 trading days | C$0.32 | C$0.26 – C$0.40 |
| 90 trading days | C$0.31 | C$0.23 – C$0.40 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Medicenna's Stock Climbs 2.44% in One Day
With a market cap of CA$33.8 million, Medicenna's stock performance reflects increasing interest in its innovative cancer therapies.
Bull case
Investors might feel optimistic about Medicenna's ongoing clinical trials and the recent positive data presentations, especially regarding its MDNA113 program. These promising results could strengthen its market position and attract more investment.
Bear case
Despite the recent gains, potential investors should stay cautious. The biopharmaceutical sector is known for its volatility and reliance on clinical trial outcomes. Any setbacks in drug development could negatively impact the stock price.
Recent Performance Overview
Medicenna's stock performance over the last trading day shows a positive trend, gaining 2.44% to close at CA$0.42. This increase is significant given the company's market cap of CA$33.8 million, indicating heightened investor interest.
Factors Behind the Rise
The recent increase in Medicenna's stock can be linked to its ongoing clinical studies, particularly the encouraging results from its MDNA113 program presented at the AACR Annual Meeting. Such developments can greatly influence investor sentiment and stock performance.
Looking Ahead
As Medicenna continues to progress with its clinical trials and strategic initiatives, investors will be closely monitoring future developments. While the recent gains are promising, potential investors should remain aware of the risks associated with biopharmaceutical investments.
Advertisement
